Ardent Health (ARDT) SVP & CAO awarded 8,859 performance-based shares

Rhea-AI Filing Summary

Byers David Raynor reported acquisition or exercise transactions in this Form 4 filing.

Ardent Health, Inc. reported that SVP & Chief Accounting Officer David Raynor Byers received a grant of 8,859 shares of common stock as a compensation award. These shares were earned based on 2024 and 2025 performance under performance-vesting restricted stock units and will vest on December 31, 2026, contingent on continued service through that date. Following this award, he directly holds 120,650 shares of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Byers David Raynor

(Last) (First) (Middle)

340 SEVEN SPRINGS WAY, SUITE 100

(Street)

BRENTWOOD TN 37027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ardent Health, Inc. [ ARDT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		A		8,859(1)	A	$0	120,650	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares earned based on 2024 and 2025 performance under performance vesting restricted stock units awarded on July 18, 2024. Pursuant to the terms of the award, the shares will vest on December 31, 2026 contingent upon service through such date.

Remarks:

	/s/ Stephen C. Petrovich, Attorney-in-Fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Ardent Health (ARDT) report for David Raynor Byers?

Ardent Health reported that SVP & Chief Accounting Officer David Raynor Byers received 8,859 shares of common stock as a grant. The award reflects performance achieved for 2024 and 2025 under previously granted performance-vesting restricted stock units.

How many Ardent Health (ARDT) shares does David Raynor Byers hold after this Form 4?

After the reported grant, David Raynor Byers holds 120,650 shares of Ardent Health common stock directly. This total includes the 8,859 newly awarded shares and represents his position as of the transaction date disclosed in the filing.

What was the price per share for the Ardent Health (ARDT) stock granted to David Raynor Byers?

The 8,859 shares of Ardent Health common stock were granted at a reported price per share of $0.00. This indicates the shares were issued as a compensation award rather than purchased in an open-market transaction or through an option exercise.

What type of equity award did Ardent Health (ARDT) grant to David Raynor Byers?

The award relates to performance-vesting restricted stock units that were originally granted on July 18, 2024. The reported 8,859 shares were earned based on 2024 and 2025 performance results tied to that prior RSU grant.

When will the newly earned Ardent Health (ARDT) shares vest for David Raynor Byers?

The 8,859 earned shares will vest on December 31, 2026, contingent upon David Raynor Byers remaining in service through that date. Until vesting, the award remains subject to this continued employment condition under the original performance RSU terms.

Is the Ardent Health (ARDT) Form 4 transaction a market purchase or sale?

The Form 4 reports a grant or award acquisition, not a market purchase or sale. Shares were issued at $0.00 per share as part of a performance-based restricted stock unit program, reflecting compensation rather than trading activity.